Pramlintide (SymlinPen)
Awaiting review, BioHarmony verdict
Not yet scored. Queued for review; until then rely on the status and sources below.
What is Pramlintide (SymlinPen)?
Pramlintide was FDA approved as Symlin and SymlinPen as an adjunct to mealtime insulin in patients with type 1 or type 2 diabetes who have not achieved desired glucose control despite optimal insulin therapy. Drugs@FDA now lists every Symlin presentation as discontinued, and the DailyMed listing records a marketing end date of January 31, 2027.
Saved on this device only.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
Primary sources
- SymlinPen (pramlintide acetate) prescribing information DailyMed, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.